Rituximab was found to be effective at inducing remission in two separate studies of severe antineutrophil cytoplasmic antibody–associated vasculitis reported in the July 15 issue of the New England Journal of Medicine.
Rituximab was found to be effective at inducing remission in two separate studies of severe antineutrophil cytoplasmic antibody–associated vasculitis reported in the July 15 issue of the New England Journal of Medicine.